Extended treatment with Kaftrio progressively increases the diversity of the microorganisms in the gut in people with cystic…
Articles by Andrea Lobo, PhD
The U.S. Food and Drug Administration (FDA) has granted fast track designation to SPL84, an experimental inhalation therapy for people…
Improvements in mucus clearance with the approved medication Trikafta — evident among patients within a month after starting treatment,…
Four years after the approval of Trikafta (elexacaftor/tezacaftor/ivacaftor) for cystic fibrosis (CF), global disparities in access to the…
A history of pancreatic inflammation, diabetes, high blood pressure, and high cholesterol may increase the risk of pancreatic cancer in…
People with advanced liver disease associated with cystic fibrosis (CF) have more pro-inflammatory bacteria in their feces relative to those…
A greater increase in body mass index (BMI), a measure of body fat, from ages 1 through 6…
The nasal microbiome — the community of microorganisms that live in the nose — obtained through nasal lavage…
Clarametyx Biosciences has completed a $33 million financing round to support its development of CMTX-101, a non-antibiotic treatment candidate for…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to BX004, BiomX’s inhaled phage therapy being…